Preliminary efficacy results
LIGHT CHAIN MYELOMA
As only two dose levels could be fully recruited and therefore no patient received more than one dose of the drug, efficacy results are limited. Clinical parameters are indicating that the activity of MM stayed stable in the 40 mg dose group during the 8 weeks of assessment while it tended to rise in the 10 mg treatment group: mean M-protein levels were 1.26 g/dl at baseline in the 40 mg cohort and 1.15 g/dl at week 8 after treatment, while in the 10 mg cohort, the baseline level was 1.58 g/dl and climbed to 2.91 g/dl at week 8.This picture was confirmed by the immunoglobulin assessments. Figure IMWG response calculated as percentage change from baseline of serum levels of immunoglobulin heavy chain or—in case of light chain myeloma—the free light chain, at week 4 and 8 after the i.v. infusion of PEG-liposomal dexamethasone phosphate. Bars show individual patients. Blue are patients in the 10 mg and orange in the 40 mg dose group